- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01509157
MDRS for Prevention of Nocturnal Hypoglycemia (MDRS)
July 15, 2013 updated by: Rabin Medical Center
Prevention of Nocturnal Hypoglycemia in Children and Young Adults With Type 1 Diabetes Using a Remote Safety and Control Diabetes Management System
The investigators have developed a unique Remote & Safety diabetes management system (MDRS) that offers real-time remote monitoring and control of glucose levels.
The system allows the supervising personal to alarm the patient and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults.The aim of this feasibility study is to evaluate the efficacy of the MDRS system in preventing nocturnal hypoglycemia in children and young adults with type 1 diabetes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Petah-Tikva, Israel, 49202
- Schneider Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 24 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Type 1 diabetes diagnosed at least 1 year prior to study entry
- Continuous subcutaneous insulin infusion pump for at least 3 month prior to study entry
- Use of continuous glucose measurement device for at least one month prior to study entry
- Age: 4-24 years old
- HbA1c < =8.5%
- No more than one severe hypoglycemia or an episode diabetic ketoacidosis within the year prior to study entry, and none within the month prior to study entry.
- Capable of reading a pump screen in English
- Capable of operating the MDRS software
- A patient older than 18 years- leaving routinely with at least one more adult(age above 18 years) capable of connecting the C&C center and properly reacting to the instructions given by the attending personal.
- A patient younger than 18 years- leaving routinely with at least two adults (age above 18 years) capable of connecting the C&C center and properly reacting to the instructions given by the attending personal.
- All participants must provide an adult independent contact person, leaving near by the participant, capable of connecting the C&C center and properly reacting to the instructions given by the attending personal. This person will be called into action in emergency cases in which the participant or his household members can not be reached.
- Capable of completing the hypoglycemia the relevant surveys
- Able to understand and sign an informed consent forms
Exclusion Criteria:
- Any significant disease or conditions, including psychiatric disorders that in the opinion of the principal investigator are likely to effect subject compliance or the subjects ability to complete the study.
- Patients participating in other device or drug studies
- Known dermal hypersensitivity to trial products or those that contain medical adhesive
- Current use of oral glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication for participation in the study.
- Inability to understand/complete the hypoglycemia fear survey
- Female subject who is pregnant or planning to become pregnant within the planned study duration
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MDRS system
Participants will be using the MDRS system combined with their regular treatment with Continuous Glucose Monitoring during nightime for 2 weeks.
The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
|
Participants will be using the MDRS system combined with their regular Continuous Glucose Monitoring during nightime for 2 weeks.
The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
|
Active Comparator: Continuous Glucose Monitoring
Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
|
Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reduction in time spent in hypoglycemia
Time Frame: 4 weeks (end of study period)
|
4 weeks (end of study period)
|
Parental fear of hypoglycemia
Time Frame: 4 weeks ( end of study pariod)
|
4 weeks ( end of study pariod)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Treatment Satisfaction
Time Frame: between week 0 (baseline) and week 4 (end of study period)
|
We will measure the change in Treatment Satisfaction using questioner and calculation of the the satisfaction score
|
between week 0 (baseline) and week 4 (end of study period)
|
Percentage of time spent in the target range
Time Frame: 4 weeks (end of study period)
|
Percentage of time spent in the target range, defined as sensor glucose level within 63-140 mg/dl
|
4 weeks (end of study period)
|
Percentage of time spent in the tight normal range
Time Frame: 4 weeks (end of study period)
|
Percentage of time spent in the tight normal range, defined as sensor glucose level within 80 to 120 mg/dl
|
4 weeks (end of study period)
|
Average and median of blood glucose levels
Time Frame: 4 weeks (end of study period)
|
4 weeks (end of study period)
|
|
Percentage of time spent below 63 mg/dl
Time Frame: 4 weeks (end of study period)
|
4 weeks (end of study period)
|
|
Percentage of time spent above 140,180,250 mg/dl
Time Frame: 4 weeks (end of study period)
|
4 weeks (end of study period)
|
|
Glucose variability
Time Frame: 4 weeks (end of study period)
|
Glucose variability measured by glucose Standard Deviation and "Kovatchev indexes"
|
4 weeks (end of study period)
|
Hypoglycemic events-number and severity of episodes
Time Frame: 4 weeks (end of study period)
|
4 weeks (end of study period)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2012
Primary Completion (Actual)
February 1, 2013
Study Completion (Actual)
April 1, 2013
Study Registration Dates
First Submitted
December 25, 2011
First Submitted That Met QC Criteria
January 11, 2012
First Posted (Estimate)
January 12, 2012
Study Record Updates
Last Update Posted (Estimate)
July 16, 2013
Last Update Submitted That Met QC Criteria
July 15, 2013
Last Verified
July 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- rmc006447ctil
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Helmholtz Zentrum MünchenRecruitingType 1 Diabetes MellitusGermany
Clinical Trials on MDRS System (Remote & Safety diabetes management system)
-
Corporacion Parc TauliTechnical University of Madrid; CIBER-BBN: Networking Research Center for Bioengineering...Completed
-
University of Alabama at BirminghamNational Institute on Minority Health and Health Disparities (NIMHD)Not yet recruitingType 2 Diabetes
-
Sinai Health SystemRecruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes | Diabetes Mellitus, Type 1United States
-
Region Jönköping CountyLinkoeping University; Region Östergötland; Uppsala County Council, Sweden; Medical... and other collaboratorsRecruitingType 2 DiabetesSweden
-
Bigfoot Biomedical Inc.Jaeb Center for Health ResearchEnrolling by invitation
-
Biotronik, Inc.Biotronik Australia Pty Ltd.; BIOTRONIK NeuroRecruitingChronic Low-back Pain | Chronic Leg PainAustralia
-
University of PittsburghCompletedDiabetes MellitusUnited States
-
Bigfoot Biomedical Inc.Profil Institute for Clinical Research, Inc.; Jaeb Center for Health ResearchCompleted
-
University of Texas at AustinRecruitingType 2 DiabetesUnited States
-
The Open University of JapanCompletedCardiovascular Diseases | Heart FailureJapan